SPA
PHAT icon

Sherbrooke Park Advisers’s Phathom Pharmaceuticals PHAT Stock Holding History

Sherbrooke Park Advisers’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-26,307
Closed -$165K – 719
2025
Q1 		$165K Buy
+26,307
New +$160K 0.08% 453

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Sherbrooke Park Advisers's PHAT Position: Q2 2025 in Review

Sherbrooke Park Advisers sold out of Phathom Pharmaceuticals (PHAT) in Q2 2025, closing a stake of 26,307 shares — an estimated $165K sold.

Sherbrooke Park Advisers first reported a position in PHAT in Q1 2025 and held it in 1 quarter. The position peaked at $165K in Q1 2025. 117 funds tracked by Wall St. Rank hold PHAT as of Q2 2025.

  • Sherbrooke Park Advisers reported no remaining Phathom Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 26,307 Phathom Pharmaceuticals shares in Q2 2025, an estimated $165K.
  • Sherbrooke Park Advisers first reported a position in Phathom Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • Sherbrooke Park Advisers's Phathom Pharmaceuticals position peaked at $165K in Q1 2025.
  • 117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.